Disturbances in placental immunology: Ready for therapeutic interventions?

Springer Seminars in Immunopathology

Volumn 27, Issue 4, 2006, Pages 477-493

  Hahn, Sinuhe ^a   Gupta, Anurag Kumar ^a   Troeger, Carolyn ^a   Rusterholz, Corinne ^a   Holzgreve, Wolfgang ^a  

^a UNIVERSITY WOMEN S HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; HLA G ANTIGEN; IMMUNOGLOBULIN; KETANSERIN; MACROPHAGE MIGRATION INHIBITION FACTOR; PHOSPHOLIPID ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANTIPHOSPHOLIPID SYNDROME; APOPTOSIS; BYSTANDER EFFECT; COMPLEMENT ACTIVATION; FETUS MALFORMATION; FETUS WASTAGE; HUMAN; HYPOXIA; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; LEUKOCYTE ACTIVATION; MACROPHAGE MIGRATION INHIBITION; MOTHER FETUS RELATIONSHIP; NATURAL KILLER CELL; PLACENTA DISORDER; PREECLAMPSIA; PRIORITY JOURNAL; RECURRENT ABORTION; REVIEW; RISK BENEFIT ANALYSIS; TH1 CELL; TH2 CELL;

ABORTION, HABITUAL; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; PLACENTA; PRE-ECLAMPSIA; PREGNANCY;

EID: 33744828253     PISSN: 03444325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00281-006-0016-5     Document Type: Review

References (90)

1. Medawar PB (1961) Immunological tolerance. Nature 189:14-17
2. Carrington B, Sacks G, Regan L (2005) Recurrent miscarriage: pathophysiology and outcome. Curr Opin Obstet Gynecol 17:591-597
3. Meroni PL, di Simone N, Testoni C, D'Asta M, Acaia B, Caruso A (2004) Antiphospholipid antibodies as cause of pregnancy loss. Lupus 13:649-652
4. Redman CW, Sargent IL (2005) Latest advances in understanding preeclampsia. Science 308:1592-1594
5. Sibai B, Dekker G, Kupfermine M (2005) Pre-eclampsia. Lancet 365:785-799
6. Hahn S, Huppertz B, Holzgreve W (2005) Fetal cells and cell free fetal nucleic acids in maternal blood: new tools to study abnormal placentation? Placenta 26:515-526
7. von Dadelszen P, Magee LA, Roberts JM (2003) Subclassification of preeclampsia. Hypertens Pregnancy 22:143-148
8. Sebire NJ, Goldin RD, Regan L (2005) Term preeclampsia is associated with minimal histopathological placental features regardless of clinical severity. J Obstet Gynaecol 25:117-118
9. Burton GJ, Jauniaux E (2004) Placental oxidative stress: from miscarriage to preeclampsia. J Soc Gynecol Investig 11:342-352
10. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA (2004) Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350:672-683
11. Robillard PY, Dekker GA, Hulsey TC (1999) Revisiting the epidemiological standard of preeclampsia: primigravidity or primipaternity? Eur J Obstet Gynecol Reprod Biol 84:37-41
12. Dekker GA, Robillard PY, Hulsey TC (1998) Immune maladaptation in the etiology of preeclampsia: a review of corroborative epidemiologic studies. Obstet Gynecol Surv 53:377-382
13. Redman CW, Sargent IL (2000) Placental debris, oxidative stress and pre-eclampsia. Placenta 21:597-602
14. Hiby SE, Walker JJ, O'shaughnessy KM, Redman CW, Carrington M, Trowsdale J, Moffett A (2004) Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J Exp Med 200:957-965
15. Chamley LW (1997) Antiphospholipid antibodies or not? The role of beta 2 glycoprotein 1 in autoantibody-mediated pregnancy loss. J Reprod Immunol 36:123-142
16. Chamley LW, Allen JL, Johnson PM (1997) Synthesis of beta2 glycoprotein 1 by the human placenta. Placenta 18:403-410
17. Chamley LW, Duncalf AM, Mitchell MD, Johnson PM (1998) Action of anticardiolipin and antibodies to beta2-glycoprotein-I on trophoblast proliferation as a mechanism for fetal death. Lancet 352:1037-1038
18. di Simone N, Castellani R, Caliandro D, Caruso A (2002) Antiphospholid antibodies regulate the expression of trophoblast cell adhesion molecules. Fertil Steril 77:805-811
19. di Simone N, Castellani R, Caliandro D, Caruso A (2001) Monoclonal anti-annexin V antibody inhibits trophoblast gonadotropin secretion and induces syncytiotrophoblast apoptosis. Biol Reprod 65:1766-1770
20. Bose P, Black S, Kadyrov M, Bartz C, Shlebak A, Regan L, Huppertz B (2004) Adverse effects of lupus anticoagulant positive blood sera on placental viability can be prevented by heparin in vitro. Am J Obstet Gynecol 191:2125-2131
21. Bose P, Kadyrov M, Goldin R, Hahn S, Backos M, Regan L, Huppertz B (2006) Aberrations of early trophoblast differentiation predispose to pregnancy failure: lessons from the anti-phospholipid syndrome. Placenta (In press) PMID 16289730
22. Bose P, Black S, Kadyrov M, Weissenborn U, Neulen J, Regan L, Huppertz B (2005) Heparin and aspirin attenuate placental apoptosis in vitro: implications for early pregnancy failure. Am J Obstet Gynecol 192:23-30
23. Chen Q, Stone PR, Woon ST, Ching LM, Hung S, McCowan LM, Chamley LW (2004) Antiphospholipid antibodies bind to activated but not resting endothelial cells: is an independent triggering event required to induce antiphospholipid antibody-mediated disease? Thromb Res 114:101-111
24. Salmon JE, Girardi G (2004) The role of complement in the antiphospholipid syndrome. Curr Dir Autoimmun 7:133-148
25. Holers VM, Girardi G, Mo L, Guthridge JM, Molina H, Pierangeli SS, Espinola R, Xiaowei LE, Mao D, Vialpando CG, Salmon JE (2002) Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 195:211-220
26. Girardi G, Berman J, Redecha P, Spruce L, Thurman JM, Kraus D, Hollmann TJ, Casali P, Caroll MC, Wetsel RA, Lambris JD, Holers VM, Salmon JE (2003) Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 112:1644-1654
27. Girardi G, Redecha P, Salmon JE (2004) Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 10:1222-1226
28. Berman J, Girardi G, Salmon JE (2005) TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol 174:485-490
29. Yui J, Garcia-Lloret M, Wegmann TG, Guilbert LJ (1994) Cytotoxicity of tumour necrosis factor-alpha and gamma-interferon against primary human placental trophoblasts. Placenta 15:819-835
30. Hristoskova S, Holzgreve W, Hahn S (2004) Anti-phospholipid and anti-DNA antibodies are not associated with the elevated release of circulatory fetal DNA in pregnancies affected by preeclampsia. Hypertens Pregnancy 23:257-268
31. Bowen RS, Moodley J, Dutton MF, Fickl H (2002) Antibodies to oxidised low-density lipoproteins and cardiolipin in pre-eclampsia and eclampsia. J Obstet Gynaecol 22:123-126
32. Ellis SA, Sargent IL, Redman CW, McMichael AJ (1986) Evidence for a novel HLA antigen found on human extravillous trophoblast and a choriocarcinoma cell line. Immunology 59:595-601
33. Hviid TV (2006) HLA-G in human reproduction: aspects of genetics, function and pregnancy complications. Hum Reprod Update (In press)
34. Hunt JS, Petroff MG, McIntire RH, Ober C (2005) HLA-G and immune tolerance in pregnancy. FASEB J 19:681-693
35. Le Bouteiller P, Pizzato N, Barakonyi A, Solier C (2003) HLA-G, pre-eclampsia, immunity and vascular events. J Reprod Immunol 59:219-234
36. Lanier LL (2005) NK cell recognition. Annu Rev Immunol 23:225-274
37. Parham P (2004) NK cells and trophoblasts: partners in pregnancy. J Exp Med 200:951-955
38. van den Heuvel MJ, Xie X, Tayade C, Peralta C, Fang Y, Leonard S, Paffaro VA Jr, Sheikhi AK, Murrant C, Croy BA (2005) A review of trafficking and activation of uterine natural killer cells. Am J Reprod Immunol 54:322-331
39. Monk JM, Leonard S, McBey BA, Croy BA (2005) Induction of murine spiral artery modification by recombinant human interferon-gamma. Placenta 26:835-838
40. Contini P, Ohio M, Poggi A, Filaci G, Indiveri F, Ferrone S, Puppo F (2003) Soluble HLA-A, -B, -C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol 33:125-134
41. Le Friec G, Laupeze B, Fardel O, Sebti Y, Pangault C, Guilloux V, Beauplet A, Fauchet R, Amiot L (2003) Soluble HLA-G inhibits human dendritic cell-triggered allogeneic T-cell proliferation without altering dendritic differentiation and maturation processes. Hum Immunol 64:752-761
42. Bahri R, Hirsch F, Josse A, Rouas-Freiss N, Bidere N, Vasquez A, Carosella ED, Charpentier B, Durrbach A (2006) Soluble HLA-G inhibits cell cycle progression in human alloreactive T lymphocytes. J Immunol 176:1331-1339
43. Goldman-Wohl DS, Ariel I, Greenfield C, Hochner-Celnikier D, Cross J, Fisher S, Yagel S (2000) Lack of human leukocyte antigen-G expression in extravillous trophoblasts is associated with pre-eclampsia. Mol Hum Reprod 6:88-95
44. Christiansen OB, Mohapeloa HP, Steffensen R, Jersild C (1997) HLA-C and -Bw typing of couples with unexplained recurrent miscarriages. J Reprod Immunol 37:63-77
45. Karhukorpi J, Laitinen T, Tiilikainen AS (1997) HLA-G polymorphism in Finnish couples with recurrent spontaneous miscarriage. Br J Obstet Gynaecol 104:1212-1214
46. Aldrich CL, Stephenson MD, Karrison T, Odem RR, Branch DW, Scott JR, Schreiber JR, Ober C (2001) HLA-G genotypes and pregnancy outcome in couples with unexplained recurrent miscarriage. Mol Hum Reprod 7:1167-1172
47. Pfeiffer KA, Fimmers R, Engels G, d van V, d van V (2001) The HLA-G genotype is potentially associated with idiopathic recurrent spontaneous abortion. Mol Hum Reprod 7:373-378
48. Sher G, Keskintepe L, Fisch JD, Acacio BA, Ahlering P, Batzofin J, Ginsburg M (2005) Soluble human leukocyte antigen G expression in phase I culture media at 46 hours after fertilization predicts pregnancy and implantation from day 3 embryo transfer. Fertil Steril 83:1410-1413
49. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, Brown C, Mellor AL (1998) Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281:1191-1193
50. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL (1999) Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 189:1363-1372
51. Santoso DI, Rogers P, Wallace EM, Manuelpillai U, Walker D, Subakir SB (2002) Localization of indoleamine 2,3-dioxygenase and 4-hydroxynonenal in normal and pre-eclamptic placentae. Placenta 23:373-379
52. Clark DA, Blois S, Kandil J, Handjiski B, Manuel J, Arck PC (2005) Reduced uterine indoleamine 2, 3-dioxygenase versus increased TH1/TH2 cytokine ratios as a basis for occult and clinical pregnancy failure in mice and humans. Am J Reprod Immunol 54:203-216
53. Chaouat G, Ledee-Bataille N, Dubanchet S, Zourbas S, Sandra O, Martal J (2004) TH1/TH2 paradigm in pregnancy: paradigm lost? Cytokines in pregnancy/early abortion: reexamining the TH1/TH2 paradigm. Int Arch Allergy Immunol 134:93-119
54. Mosmann TR, Coffman RL (1989) TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 7:145-173
55. Hahn S, Gehri R, Erb P (1995) Mechanism and biological significance of CD4-mediated cytotoxicity. Immunol Rev 146:57-79
56. Stalder T, Hahn S, Erb P (1994) Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity. J Immunol 152:1127-1133
57. Hahn S, Erb P (1999) The immunomodulatory role of CD4-positive cytotoxic T-lymphocytes in health and disease. Int Rev Immunol 18:449-464
58. Wegmann TG, Lin H, Guilbert L, Mosmann TR (1993) Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol Today 14:353-356
59. Lin H, Mosmann TR, Guilbert L, Tuntipopipat S, Wegmann TG (1993) Synthesis of T helper 2-type cytokines at the maternal-fetal interface. J Immunol 151:4562-4573
60. Fievet N, Moussa M, Tami G, Maubert B, Cot M, Deloron P, Chaouat G (2001) Plasmodium falciparum induces a Th1/Th2 disequilibrium, favoring the Th1-type pathway, in the human placenta. J Infect Dis 183:1530-1534
61. Zenclussen AC, Fest S, Joachim R, Klapp BF, Arck PC (2004) Introducing a mouse model for pre-eclampsia: adoptive transfer of activated Th1 cells leads to pre-eclampsia-like symptoms exclusively in pregnant mice. Eur J Immunol 34:377-387
62. Sacks G, Sargent I, Redman C (1999) An innate view of human pregnancy. Immunol Today 20:114-118
63. Sargent IL, Germain SJ, Sacks, GP, Kumar S, Redman CW (2003) Trophoblast deportation and the maternal inflammatory response in pre-eclampsia. J Reprod Immunol 59:153-160
64. Huppertz B, Kingdom J, Caniggia I, Desoye G, Black S, Korr H, Kaufmann P (2003) Hypoxia favours necrotic versus apoptotic shedding of placental syncytiotrophoblast into the maternal circulation. Placenta 24:181-190
65. Degenne D, Khalfoun B, Bardos P (1986) In vitro inhibitory effect of human syncytiotrophoblast plasma membranes on the cytolytic activities of CTL and NK cells. Am J Reprod Immunol Microbiol 12:106-110
66. Thibault G, Degenne D, Lacord M, Guillaumin JM, Girard AC, Bardos P (1992) Inhibitory effect of human syncytiotrophoblast plasma membrane vesicles on Jurkat cells activated by phorbol ester and calcium ionophore. Cell Immunol 139:259-267
67. Knight M, Redman CW, Linton EA, Sargent IL (1998) Shedding of syncytiotrophoblast microvilli into the maternal circulation in pre-eclamptic pregnancies. Br J Obstet Gynaecol 105:632-640
68. Gupta AK, Rusterholz C, Huppertz B, Malek A, Schneider H, Holzgreve W, Hahn S (2005) A comparative study of the effect of three different syncytiotrophoblast micro-particles preparations on endothelial cells. Placenta 26:59-66
69. Gupta AK, Rusterholz C, Holzgreve W, Hahn S (2005) Syncytiotrophoblast micro-particles do not induce apoptosis in peripheral T lymphocytes, but differ in their activity depending on the mode of preparation. J Reprod Immunol 68:15-26
70. Rusterholz C, Gupta AK, Huppertz B, Holzgreve W, Hahn S (2005) Soluble factors released by placental villous tissue: interleukin-1 is a potential mediator of endothelial dysfunction. Am J Obstet Gynecol 192:618-624
71. Gupta AK, Holzgreve W, Hahn S (2005) Microparticle-free placentally derived soluble factors downmodulate the response of activated T cells. Hum Immunol 66:977-984
72. Sacks GP, Studena K, Sargent IL, Redman CW (1997) CD11b expression on circulating neutrophils in pre-eclampsia. Clin Sci (Lond) 93:187-189
73. Brinkman V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y, Zychlinsky A (2004) Neutrophil extracellular traps kill bacteria. Science 303:1532-1535
74. Hahn S, Holzgreve W (2002) Fetal cells and cell-free fetal DNA in maternal blood: new insights into pre-eclampsia. Hum Reprod Update 8:501-508
75. Bloom BR, Bennett B (1966) Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 153:80-82
76. Mitchell RA (2004) Mechanisms and effectors of MIF-dependent promotion of tumourigenesis. Cell Signal 16:13-19
77. Apte RS, Sinha D, Mayhew E, Wistow GJ, Niederkorn JY (1998) Cutting edge: role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege. J Immunol 160:5693-5696
78. Niederkorn JY, Wang S (2005) Immune privilege of the eye and fetus: parallel universes? Transplantation 80:1139-1144
79. Todros T, Bontempo S, Piccoli E, Ietta F, Romagnoli R, Biolcati M, Castellucci M, Paulesu L (2005) Increased levels of macrophage migration inhibitory factor (MFF) in preeclampsia. Eur J Obstet Gynecol Reprod Biol 123(2):162-166
80. Hristoskova S, Holzgreve W, Zhong XY, Hahn S (2005) Macrophage migration inhibition factor is elevated in pregnancy, but not to a greater extent in preeclampsia. Arch Gynecol Obstet 1-4:1-4
81. Holzgreve W, Hahn S (1999) Novel molecular biological approaches for the diagnosis of preeclampsia. Clin Chem 45:451-452
82. Shoenfeld Y, Katz U (2005) IVIg therapy in autoimmunity and related disorders: our experience with a large cohort of patients. Autoimmunity 38:123-137
83. Pandey MK, Rani R, Agrawal S (2005) An update in recurrent spontaneous abortion. Arch Gynecol Obstet 272:95-108
84. Pandey MK, Agrawal S (2004) Induction of MLR-Bf and protection of fetal loss: a current double blind randomized trial of paternal lymphocyte immunization for women with recurrent spontaneous abortion. Int Immunopharmacol 4:289-298
85. Di Nisio M, Peters L, Middeldorp S (2005) Anticoagulants for the treatment of recurrent pregnancy loss in women without antiphospholipid syndrome. Cochrane Database Syst Rev CD004734
86. Carp HJ, Dirnfeld M, Dor J, Grudzinskas JG (2004) ART in recurrent miscarriage: preimplantation genetic diagnosis/screening or surrogacy? Hum Reprod 19:1502-1505
87. Audibert F (2005) Screening for pre-eclampsia: the quest for the Holy Grail? Lancet 365:1367-1369
88. Rumbold A, Middleton P, Crowther CA (2005) Vitamin supplementation for preventing miscarriage. Cochrane Database Syst Rev CD004073
89. Oettle C, Hall D, Roux A, Grove D (2005) Early onset severe pre-eclampsia: expectant management at a secondary hospital in close association with a tertiary institution. BJOG 112:84-88
90. Hanff LM, Visser W, Roofthooft DW, Venues A, Hop WC, Steegers EA, Vulto AG (2005) Insufficient efficacy of intravenous ketanserin in severe early-onset pre-eclampsia. Eur J Obstet Gynecol Reprod Biol